Ionix: Eye on peripheral pain

Going through the list of compounds in the clinic to treat pain is a depressing exercise. With the exception of the COX-2 inhibitors and novel ways to deliver opioids, few new approaches have been seen in the past 50 years or more. Ionix Pharmaceuticals Ltd. is stepping into that space with a focus on treatments for inflammatory and neuropathic pain that block peripheral nervous system targets, hoping for selective efficacy without CNS side effects.

The formation of the company marks the

Read the full 802 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers